S&P Futures
4,074.75 -15.25 (-0.37%) Dow Futures
34,018.00 -138.00 (-0.40%) Nasdaq Futures
12,118.75 -33.25 (-0.27%) Russell 2000 Futures
1,932.80 -6.60 (-0.34%) Crude Oil
78.90 +0.03 (+0.04%) Gold
1,940.30 -5.00 (-0.26%)
Applied Molecular Transport Inc. (AMTI)
After hours:
- Benzinga
Applied Molecular's Ulcerative Colitis Candidate Fails To Separate From Placebo In Untreated Patients
Applied Molecular Transport Inc (NASDAQ: AMTI) announced topline Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis (UC). The clinical remission (CR) rate in patients treated with AMT-101 monotherapy was 17.1% (12/70 patients) compared to a CR rate of 20.0% (7/35 patients) with placebo, which was above the company's baseline assumption for placebo CR rates based on published data in moderate-to-seve
- GlobeNewswire
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was well-tolerated – Planned Phase 1b trial for the company’s second clinical asset, AMT-126, in UC patients – Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis – Strong cash position of $76M reported in Q3 2022 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq:
- Simply Wall St.
Aaron VanDevender Is The Independent Director of Applied Molecular Transport Inc. (NASDAQ:AMTI) And They Just Picked Up 239% More Shares
Potential Applied Molecular Transport Inc. ( NASDAQ:AMTI ) shareholders may wish to note that the Independent Director...
